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Klinik und Poliklinik IV Ludwig-Maximilians-Universität München, 80336 Munich, Germany; 21Klinik für
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Background: Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In the
evaluation of AI, it is generally recommended that PCC be excluded bymeasurement of plasma-free or
24-hour urinary fractionated metanephrines. However, recent studies suggest that biochemical ex-
clusion of PCC not be performed for lesionswith CT characteristics of an adrenocortical adenoma (ACA).
Aim: To determine the proportion of PCCs with ACA-like attenuation or contrast washout on CT.
Methods: For this multicenter retrospective study, two central investigators independently ana-
lyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on tumor size,
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unenhanced Hounsfield units (HU), absolute percentage washout (APW), and relative percentage
washout (RPW) were collected in addition to clinical parameters.
Results: Among the 376 PCCs for which unenhanced attenuation data were available, 374 had an
attenuation of.10 HU (99.5%). In the two exceptions (0.5%), unenhanced attenuation was exactly
10 HU, which lies just within the range of#10 HU that would suggest a diagnosis of ACA. Of 76 PCCs
with unenhanced HU . 10 and available washout data, 22 (28.9%) had a high APW and/or RPW,
suggestive of ACA.
Conclusion: Based on the lack of PCCs with an unenhanced attenuation of ,10 HU and the low
proportion (0.5%) of PCCs with an attenuation of 10 HU, it seems reasonable to abstain from
biochemical testing for PCC in AIs with an unenhanced attenuation of #10 HU. The assessment of
contrast washout, however, is unreliable for ruling out PCC. (J Clin Endocrinol Metab 104: 312–318,
2019)
Adrenal pheochromocytomas (PCCs) and extra-adrenalsympathetic paragangliomas are rare tumors that arise
from catecholamine-producing chromaffin cells (1). Up
to 40% of chromaffin tumors are associated with
hereditable tumor syndromes (2–5). The most accurate
diagnostic test for the biochemical diagnosis of these
tumors is the measurement of plasma free or 24-hour
urinary fractionated metanephrines (6, 7). Typical symp-
toms and signs include headache, tremors, palpitations,
sweating, and anxiety. However, up to 25% of patients do
not have signs and symptoms, and up to 30% of PCCs are
diagnosed following the discovery of an adrenal inci-
dentaloma (AI) (7, 8).
The prevalence of AI on thoracic, abdominal, and
pelvic CT ranges between 1.0% and 8.7% depending on
age (9–14). Most AIs are adrenocortical adenoma (ACA)
(12). Less prevalent causes are myelolipomas, cysts,
adrenocortical carcinoma, and metastases from other
malignancies. PCCs account for up to 7% of AIs (7).
Unlike in situations when substantial adrenal hormone
secretion or malignancy are suspected, no treatment is
indicated for benign, nonfunctioning ACA. In 2016, the
European Society of Endocrinology (ESE) in collabora-
tion with the EuropeanNetwork for the Study of Adrenal
Tumors (ENSAT) published a guideline to provide cli-
nicians with evidence-based recommendations for clini-
cal management of patients with AIs (7). This guideline
adapts a generally accepted approach in the evaluation of
AI by taking into account quantitative CT characteristics.
An attenuation of #10 Hounsfield units (HU) on unen-
hanced CT or an absolute percentage washout (APW) of
$60% or a relative percentage washout (RPW) of $40%
on CT with delayed washout after 10 to 15 minutes are
considered suggestive of ACA.
However, the guidelines and an accompanying meta-
analysis (15) clearly indicated that unenhanced CT is the
only reliable method to differentiate benign frommalignant
adrenal tumors. In addition, the guideline recommended
that an endocrine work-up for AI be performed, including
the measurement of plasma-free or 24-hour urinary frac-
tionated metanephrines. However, the guideline also
mentioned that it would be reasonable to avoid biochemical
testing for PCC in patients who have AI with an unen-
hanced attenuation of #10 HU. Nevertheless, the authors
acknowledged that only two small studies were published
on this topic (16, 17). The findings in the latter studies
require confirmation in more patients before substantiated
statements can be made.
Of note, PCCs demonstrating an attenuation of#10 HU
have been described, albeit rarely, in the literature (18, 19).
Hence, in this international multicenter study, we retrospec-
tively evaluated the quantitative CT characteristics of PCCs,
as indicated in the radiological reports, to assess the pro-
portion and associated characteristics of PCCs with an ACA-
like attenuation on CT, taking into account both unenhanced
attenuation and contrast washout measurements.
Methods
Patients
We included patients with a histologically proven PCC
(single or multiple) who had undergone preoperative CT [i.e.,
unenhanced CT (with or without contrast-enhanced CT) or
contrast washout CT]. Patients with only postcontrast CT were
not eligible for inclusion. Patients had been diagnosed and
treated in centers affiliated with ENSAT. Participating ENSAT
centers were the Mayo Clinic, Rochester, Minnesota (n = 153);
Radboud University Medical Center, Nijmegen, Netherlands
(n = 46); University Hospital Center Zagreb, Zagreb, Croatia
(n = 43); Carol Davila University of Medicine and Pharmacy,
Bucharest, Romania (n = 42); Medical University of Warsaw,
Warsaw, Poland (n = 33); CHU de Bordeaux, Pessac, France
(n = 29); University Medical Center Groningen, Groningen,
Netherlands (n = 28); University Hospital of Florence, Florence,
Italy (n = 21); University of Birmingham, Birmingham, United
Kingdom (n = 20); Center Hospitalier de l’Université de
Montréal, Montreal, Quebec, Canada (n = 19); Hospices Civils
de Lyon, Lyon, France (n = 17); University Hospital of
Wuerzburg,Wuerzburg, Germany (n = 17); University Hospital
of Krakow, Krakow, Poland (n = 16); Cambridge University
Hospitals, Cambridge, United Kingdom (n = 12); Endocrinology
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in Charlottenburg, Berlin, Germany (n = 12); Center Hos-
pitalier Universitaire de Liege, Liege, Belgium (n = 10);
Medizinische Klinik und Poliklinik IV Ludwig-Maximilians-
Universität München, Munich, Germany (n = 10); Hospital
General Universitario de Albacete, Albacete, Spain (n = 5). Pa-
tients provided informed consent, under ENSAT or local in-
stitutional protocol, when required.
Two hundred fourteen patients from the two Dutch centers
were also included in a previous study on this topic by
Buitenwerf et al. (20). In the latter study, a central re-evaluation
of CT images was performed to calculate unenhanced atten-
uation, whereas in the current study, both unenhanced atten-
uation and contrast washout were analyzed based on locally
generated CT reports. Additional inclusion criteria were age at
diagnosis $18 years, a diagnosis in or after 2000, availability
of the CT report, and clinical annotations (age, sex, and un-
derlying hereditary syndrome).
Biochemical testing and imaging
Biochemical testing, usually by measurement of plasma-
free or 24-hour urinary fractionated metanephrines, was
performed according to local protocols with corresponding
reference values. If metanephrines were not available, 24-hour
urine or plasma catecholamines were used, in order of pref-
erence. Biochemical phenotypes were categorized as “adren-
ergic,” “noradrenergic,” or “normal.” The phenotype was
classified as “adrenergic” when the increment of meta-
nephrines, relative to the upper limits of normal, exceeded 5%
of the combined metanephrine and normetanephrine in-
crements. Patients in whom these criteria were not fulfilled and
in whom normetanephrine levels exceeded the upper limits of
normal were classified as “noradrenergic” (21). In addition,
CT scans were obtained according to local protocols regarding
contrast procedure, acquisition and reconstruction parame-
ters, and approach to drawing the region of interest for HU
measurements.
Evaluation of CT reports
Anonymized imaging reports of preoperative CT scans,
generated by local radiologists as part of routine diagnostic
evaluation, were submitted for central analysis. The reports
were evaluated and scored independently by two observers
(L.C. and J.A.W.V.H.) who were blinded to the clinical in-
formation. Type of CT examination and field of view, number
and location of lesions, tumor size, unenhanced HU, APW and
RPW were considered. When multiple unenhanced HU values
were mentioned, the highest value was chosen for analysis.
When the local report did not mention values for APW/RPW,
APW and RPW were calculated according to the formulas
below, provided that the required parameters were available.
APW ¼ HU portal venous phase-HU delayed phase
HU portal venous phase-HU unenhanced
3 100%
RPW ¼ HU portal venous phase-HU delayed phase
HU portal venous phase
3 100%
PCCs were classified as ACA-like according to quantitative CT
characteristics in case one of the following criteria were fulfilled:
(i) attenuation on unenhanced CT # 10 HU or (ii) attenuation
on unenhanced CT $ 10 HU and APW $ 60% and/or
RPW $ 40%.
Data management and statistical analysis
Statistical analysis was performed with SPSS software,
version 17.0 for Windows (IBM Inc., Armonk, NY). Clinical
characteristics were compared between patients with PCC who
had and did not have an ACA-like attenuation based on
quantitative criteria. Characteristics were compared by using an
unpaired t test if variables were continuous or a x2 test if
variables were categorical. A two-sided P value of , 0.05 was
considered to indicate a statistically significant difference.
Results
In total, 1011 cases of PCC and extra-adrenal sympa-
thetic paragangliomas were screened for eligibility by the
local investigators at the 18 participating centers. Four
hundred seven cases were excluded, mainly because of the
performance of postcontrast CT only (n = 305). After
central review, 71 additional cases were excluded on the
basis of a diagnosis of extra-adrenal paraganglioma rather
than PCC (n = 25), lack of CT report (n = 21), incomplete
CT report (n = 14), age ,18 years (n = 5), lack of his-
tological proof of PCC (n = 4), and performance of
postcontrast CT only (n = 2). Of the remaining 533 pa-
tients with 548 histologically confirmed PCCs, quantita-
tive CT characteristics were available in 368 patients with
382 PCCs (376 unenhanced HUwith or without washout
and 6 washout only). The clinical characteristics and in-
formation regarding HU and maximum diameter of PCCs
are given in Table 1. The distribution of unenhanced at-
tenuation (in HU) is reported in Fig. 1. Details on CT scan
protocols and availability of quantitative data from ra-
diology reports are given in Table 2.
PCCs with ACA-like attenuation or washout
Of the 376 PCCs for which unenhanced attenuationwas
available, 374 had an attenuation of .10 HU (99.5%)
(Fig. 2). In the two exceptions (0.5%), unenhanced
Table 1. Characteristics of Patients (n = 368) and
Lesions (n = 382) for Whom Quantitative CT
Characteristics Were Available
Characteristic Value
Men, n (%) 163 (44.2)
Mean age at diagnosis 6 SD, y 54.01 6 15.05
Biochemical phenotype, n (%)
Adrenergic 200 (54.3)
Noradrenergic 111 (30.1)
Normal values 18 (4.8)
Unknown 39 (10.5)
Hereditary syndrome, n (%) 60 (16.3)a
Mean maximum
diameter 6 SD, mm
42.73 6 21.96 (n = 306)
Mean unenhanced
attenuation 6 SD, HU
35.04 6 10.95 (n = 375)
aRET (n =32), VHL (n = 11), NF1 (n = 11), SDHB (n = 2), SDHD (n=2),
MAX (n = 1), and SDHAF2 (n = 1).
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attenuation was exactly 10 HU, which lies just within the
range of the#10 HU cutoff that would suggest a diagnosis
of ACA (22). Of these two PCCs, the histology reports were
re-evaluated. The first lesion was a 42-mm right adrenal
PCCwith extensive central hemorrhage. Preoperative urine
catecholamine values were reported to be in the normal
range; however, metanephrines were not measured. The
second lesionwas a 48-mm left adrenal PCC that contained
areas of prominent nodular adrenocortical hyperplasia
besides PCC. No information on the biochemical pheno-
type could be retrieved.
Of 76 PCCs with unenhanced HU. 10 and available
washout, 22 (28.9%) had an APW $ 60% and/or
an RPW $ 40%, suggestive of ACA. In one additional
PCC, APW/RPW was high as well, but unenhanced
attenuation was unavailable. The local radiologists re-
ported on six additional lesions with characteristics of
ACA. The reasons for this, however, could not be verified
because washout data were unavailable; in the two cases
where unenhanced attenuation was mentioned, it
was .10 HU.
The PCCs with an unenhanced attenuation of .10
HU and high APW and/or RPW (n = 22) did not differ
from those with an unenhanced attenuation of .10 HU
and low washout (n = 54) with respect to sex, tumor size,
and hereditary syndrome (data not shown).
Of 548 PCCs, 282 (51.4%) were initially discovered
as AI in 276 patients. One of 199 lesions [lesion 1 in
online repository (22)] with available quantitative data
was among the two lesions with 10 HU. In this subgroup,
Figure 1. Distribution of unenhanced attenuation (HU, box-and-whiskers plot). Outliers (open circle); extreme values (asterisk); median (vertical
line); 25% to 75% (box); 95% CI (whiskers).
Table 2. CT Protocols and Availability of Quantitative Data From Radiological Reports for PCCs
Quantitative Data All CT Scans






Total 94 (17.2) 117 (21.4) 148 (27.0) 189 (34.5)
Unenhanced HU only 298 (54.4) 55 (58.5) 40 (34.2) 24 (16.2) 179 (94.7)
Unenhanced HU and APW/RPW 78 (14.2) NA NA 77 (52.0) 1 (0.5)
APW/RPW only 6 (1.1) NA NA 6 (4.1) NA
None 166 (30.3) 39 (41.5) 77 (65.8) 41(27.7) 9 (4.8)
Abbreviation: NA, not available.
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of 29 PCCs with unenhanced HU . 10 and available
washout, 10 (34.4%) had a high APW and/or RPW.
Discussion
We retrospectively evaluated the CT characteristics of
PCC in the largest international cohort to date. Our
main goal was to determine the proportion of PCCs
with an ACA-like appearance based on a low unen-
hanced attenuation or a high contrast washout. The
analysis was based on locally generated radiological
reports. Unenhanced HU values were available for 376
of 548 histologically confirmed PCCs, two of which
(0.5%) exhibited an attenuation of exactly 10 HU,
consistent with an ACA-like attenuation according to
recent ESE/ENSAT guidelines. In addition, among 76
PCCs with unenhanced HU . 10 and available
washout, 22 (28.9%) showed a high APW and/or RPW,
incorrectly suggesting ACA.
In 2016, ESE/ENSAT provided clinical practice guide-
lines for the management of patients with AIs. The
guidelines recommended that, as part of the endocrine
workup, PCC should be excluded by measurement of
plasma free or 24-hour urinary fractionated meta-
nephrines in all AIs. However, the guidelines stated that
an exception could be made for cases in which a
non–contrast-enhanced CT attenuation was#10 HU. A
disclaimer was made that the evidence to support this
exception was minimal, with two studies that showed a
low likelihood of a PCC among adrenal lesions that
were radiologically suggestive of ACA (16, 17). Sane
et al. (16) examined whether PCC could be ruled out as
cause of AIs on the basis of unenhanced attenuation
values only. They retrospectively evaluated a cohort of
174 patients with AI. Unenhanced attenuation was
available for 115 tumors. Nine patients had a PCC, and
in none of these tumors was the unenhanced HU , 10.
They concluded that routine measurement of meta-
nephrines is unnecessary in an asymptomatic patient
with AI, provided that the lesion is of low attenuation,
small, and homogenous. Schalin-Jäntti et al. (17)
performed a 5-year prospective follow-up study of 56
patients with 69 lipid-rich (i.e., low attenuation) AIs.
They found that 24-hour urinary metanephrines were
normal at baseline as well as during follow-up. In ad-
dition, Jun et al. (19) studied 251 patients with AI and
had similar results, leading to the conclusion that for
small lesions (AI size # 3 cm), noncontrast CT can
substitute for biochemical testing for PCC. Neverthe-
less, all of the conclusions and recommendations made
in these previous studies are based on small subsets of
PCCs among cohorts of patients with AIs.
Rather than taking AI as a starting point, in the current
study and in one previous report, primarily patients with
PCC were selected. Buitenwerf et al. (20) recently
conducted a retrospective study including 214 patients
with 222 histologically proven PCCs. Two expert radi-
ologists independently re-evaluated the CT scans. Only 1
PCC of 222 demonstrated an attenuation value of ,10
HU. This was a rare case of ACTH-dependent Cushing
disease caused by a PCC. In the current study, we found a
similarly low proportion (0.5%) of PCCs with an unen-
hanced attenuation of#10 HU. In fact, none of the PCCs
had an unenhanced attenuation ,10 HU; in only two
PCCs it was exactly 10 HU. In these two cases, histology
possibly provided some explanation. Hemorrhage, ne-
crosis, and additional adrenocortical changes (23) may
result in intralesional heterogeneity, emphasizing the im-
portance of selecting the proper region of interest for the
assessment of attenuation.
Figure 2. CT characteristics of PCCs. High washout: absolute $60% and/or relative $40%; low washout: absolute ,60% and/or relative
,40%. NA, not available.
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In ;70% of AIs, attenuation values are #10 HU.
This illustrates the large number of patients who might
benefit from implementing radiological selection to
determine in which patients biochemical screening is
needed as a second-line test to rule out PCC (15).
Approximately 2000 patients with adrenal incidenta-
loma and an attenuation value #10 HU would need to
be biochemically screened to diagnose one case of PCC,
assuming a 7% prevalence of PCC in the AI pop-
ulation, 70% frequency of attenuation #10 HU, and a
false-negative rate of 0.5% of radiological classifica-
tion as determined in the current study [2857 AIs in
total, including 2000 AIs with #10 HU (70% of 2857)
and 200 PCCs (7% of 2857), of which one (0.5% of
200) is misclassified by CT]. In our opinion, this ob-
servation justifies omitting biochemical screening in
low-attenuation AIs to prevent false-positive test re-
sults and unnecessary costs. In the given example
of 2000 low-attenuation AIs, based on $50 cost of
metanephrine measurement, omitting biochemical
testing would result in an immediate cost reduction of
$100,000. In the context of a specificity of plasma
metanephrines of ;80% to 90% (1), the true cost
reduction is expected to be (much) higher when taking
into account follow-up investigations prompted by
false-positive biochemical testing results that could
have been prevented.
Besides unenhanced HU, contrast washout rates are
routinely used for the evaluation of adrenal lesions. Most
ACAs with an unenhanced HU . 10 exhibit a high
washout. Conversely, a high washout does not rule out
PCC. We found that in almost one third of PCCs with
available APW/RPW data, washout was high. This is in
line with a previously meta-analysis of 10 studies byWoo
et al. (24). They reported a rate of PCCs with a high
washout pattern of 35%. Washout data for AI should
therefore not be used to determine whether biochemical
testing should be done.
This study had several limitations. It was a retro-
spective study of locally generated radiology reports from
different centers using different CT machines, settings,
and contrast protocols. Drawing of the region of interest
for the calculation of radiodensity was done at the dis-
cretion of the local radiologist. The impact of these
potential confounders, however, is probably limited,
inducing minimal variations in attenuation, estimated at
1 to 2 HU (20, 25). In addition, many cases were ex-
cluded because of the availability of postcontrast CT
scans only. The detail with which different quantitative
parameters were reported varied considerably, leading to
missing data. On the other hand, the data were extracted
directly from clinical practice and thus are representative
of "real life."
Conclusion
On the basis of the lack of PCCs with an unenhanced
attenuation of ,10 HU and the low proportion (0.5%)
of PCCs with an attenuation of 10 HU, it seems rea-
sonable to abstain from biochemical testing for PCC in
AIs with an unenhanced attenuation #10 HU. The as-
sessment of contrast washout, however, is unreliable for
ruling out PCC.
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